DOCSLIB.ORG

Etest Application Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Etest Application Guide 16273B - en - 2012/07 ETEST APPLICATION GUIDE AEROBES RECOMMENDED INOCULUM INCUBATION SPECIFIC QUALITY CONTROL ORGANISM MEDIA 6) SUGGESTED MIC PANEL 3) COMMENTS 4) PHENOTYPE Suspension Temperature/ McF equivalent Time (h) Strain ATCC® medium Atmosphere Staphylococcus 29213TM ≤ 4 mg/L 35 ± 2°C MHA 0.5 Saline Cefoxitin (FX) 18-24h aureus Ambient air S. aureus 43300TM > 4 mg/L - Phenotype interpretation: MRSA OX ≥ 4 µg/mL and Mueller Hinton agar Oxacillin (OX) 35 ± 2°C TM XL ≥ 8 µg/mL 0.5-1 Saline 24h S. aureus 43300 (MHA) + 2% NaCl Amoxicillin/clavulanic acid (XL) Ambient air - Heavier inoculum improves detection of low level R - Phenotype interpretation: Oxacillin (OX) 35 ± 2°C BORSA MHA + 2% NaCl 0.5-1 Saline 24h S. aureus 29213TM OX ≥ 4 µg/mL and Amoxicillin/clavulanic acid (XL) Ambient air XL ≤ 4 µg/mL - Phenotype interpretation: OX ≥ 0.5 µg/mL Mueller Hinton agar 35 ± 2°C MRCNS 0.5-1 Saline Oxacillin (OX) 48h S. aureus 43300TM - Heavier inoculum (MHA) + 2% NaCl Ambient air improves detection of low Staphylococci level R - 0.1 mL inoculum/ 90mm plate - Phenotype interpretation: S. aureus VA ≥ 8µg/mL and 1) 24h. VISA/hVISA Brain Heart Infusion Vancomycin (VA) 35 ± 2°C QC ranges: TM TP ≥ 8µg/mL, 2 BHI broth Confirm at 29213 (macromethod) agar (BHI) 1) Teicoplanin (TP) 1) Ambient air TP = 0.5-2 µg/mL OR 48h VA = 1-4 µg/mL TP ≥12 µg/mL (alone) = VISA/hVISA - Confirm VISA/hVISA by PAP 18-24h. S. aureus 29213TM Etest GRD2) (Vancomycin (VA) / 35 ± 2°C - Confirm VISA/hVISA by VISA/hVISA MHA + 5% blood 0.5 BHI broth Confirm at S. aureus 700698TM Teicoplanin (TP) 1)) Ambient air PAP 48h S. aureus 700699TM - Phenotype interpretation: VISA/VRSA 35 ± 2°C VA ≥ 4µg/mL = VISA (standard MHA 0.5 Saline Vancomycin (VA) 24h S. aureus 29213TM Ambient air method) VA ≥ 16µg/mL = VRSA (CLSI) bioMérieux SA English - 1 Etest® Application Guide 16273B - en - 2012/07 RECOMMENDED INOCULUM INCUBATION SPECIFIC QUALITY CONTROL ORGANISM MEDIA 6) SUGGESTED MIC PANEL 3) COMMENTS 4) PHENOTYPE Suspension Temperature/ McF equivalent Time (h) Strain ATCC® medium Atmosphere Clindamycin (CM) Daptomycin (DPC) MRSA Linezolid (LZ) 16-20h. 35 ± 2°C Secondary MHA 0.5 Saline Vancomycin (VA) VA and TP S. aureus 29213TM Ambient air panel Teicoplanin (TP) 1) full 24h Quinupristin/dalfopristin (QDA) Rifampicin (RI) 1) Staphylococci Benzylpenicillin (PG) Erythromycin (EM) Non-MRSA Linezolid (LZ) 16-20h. 35 ± 2°C secondary MHA 0.5 Saline Trimethoprim/sulfamethoxazole (TS) VA and TP S. aureus 29213TM Ambient air panel Vancomycin (VA) full 24h Teicoplanin (TP) 1) Ciprofloxacin (CI) Ampicillin (AM) Daptomycin (DPC) 16-20h. Linezolid (LZ) Confirm VA 35 ± 2°C MHA 0.5 Saline Quinupristin/dalfopristin (QDA) E. faecalis 29212TM and TP at Ambient air Vancomycin (VA) 24h Teicoplanin (TP) 1) Minocycline (MC) Enterococci - Heavier inoculum preferable E. faecalis - SM > 1024 µg/mL or 24h. QC ranges: GM > 512 µg/mL = Gentamicin (GM) high range 35 ± 2°C HLAR MHA 0.5-1 Saline Confirm SM GM = 4-16 µg/mL 29212TM positive HLAR (CLSI) Streptomycin (SM) high range 1) Ambient air at 48h SM = 64–256 µg/mL - SM > 512 µg/mL or GM > 128 µg/mL = positive HLAR (EUCAST) Gentamicin (GM) Piperacillin/ tazobactam (PTc) 0.5 Cefepime (PM) 35 ± 2°C Escherichia coli 25922TM MHA (1 for mucoid Saline 16-20h Ciprofloxacin (CI) Ambient air E. coli 35218TM organisms) Imipenem (IP) (PTc) Aztreonam (AT) Enterobacteriaceae Cefotaxime/cefotaxime + clavulanic E. coli 35218TM acid (CT/CTL) Klebsiella 700603TM 0.5 Ceftazidime/ceftazidime + clavulanic 35 ± 2°C pneumoniae - Investigate ND results by ESBL MHA (1 for mucoid Saline 16-20h acid (TZ/TZL) Ambient air (ESBL positive) an alternative method organisms) Cefepime/cefepime + clavulanic acid Pseudomonas 27853TM (PM/PML) 1) aeruginosa bioMérieux SA English - 2 Etest® Application Guide 16273B - en - 2012/07 RECOMMENDED INOCULUM INCUBATION SPECIFIC QUALITY CONTROL ORGANISM MEDIA 6) SUGGESTED MIC PANEL 3) COMMENTS 4) PHENOTYPE Suspension Temperature/ McF equivalent Time (h) Strain ATCC® medium Atmosphere 0.5 MBL MP/MPI Meropenem/Meropenem +EDTA 35 ± 2°C K. pneumoniae 700603TM - Investigate ND results by MHA (1 for mucoid Saline 16-20h. 1) (MP/MPI) Ambient air K. pneumoniae BAA-2146TM an alternative method organisms) Enterobacteriaceae Klebsiella 700603TM pneumoniae Cefotetan/Cefotetan + Cloxacillin 35 ± 2°C - Investigate ND results by AmpC 2) MHA 0.5 Saline 16-20h (negative) (CN/CNI) Ambient air an alternative method K. pneumoniae BAA-1144TM (positive) Ceftazidime (TZ) Gentamicin (GM) 0.5 16-20h. Aztreonam (AT) 35 ± 2°C P. aeruginosa 27853TM MHA (1 for mucoid Saline 48h for slow Ciprofloxacin (CI) Ambient air E. coli 35218TM organisms) growers Imipenem (IP) (PTc) Pseudomonas spp. Piperacillin/tazobactam (PTc) P. aeruginosa 27853TM 0.5 16-20h. 35 ± 2°C (negative) - Investigate ND results by MBL IP/IPI 1) MHA (1 for mucoid Saline Imipenem/imipenem + EDTA (IP/IPI) 48h for slow Ambient air Stenotrophomonas 13636TM an alternative method organisms) growers maltophilia (positive) Ceftazidime (TZ) Meropenem (MP) 0.5 20-24h. Amikacin (AK) 35 ± 2°C P. aeruginosa 27853TM MHA (1 for mucoid Saline 48h for slow Ampicillin/sulbactam (AB) Ambient air E. coli 35218TM (AB) organisms) growers Levofloxacin (LE) Acinetobacter spp. Minocycline (MC) P. aeruginosa 27853TM 0.5 16-20h. 35 ± 2°C (negative) - Investigate ND results by MBL IP/IPI 1) MHA (1 for mucoid Saline Imipenem/imipenem + EDTA (IP/IPI) 48h for slow Ambient air Stenotrophomonas 13636TM an alternative method organisms) growers maltophilia (positive) Trimethoprim/sulfamethoxazole (TS) 0.5 Ceftazidime (TZ) 20-24h. 35 ± 2°C Burkholderia cepacia MHA (1 for mucoid Saline Levofloxacin (LE) 48h for slow E. coli 25922TM Ambient air organisms) Meropenem (MP) growers Minocycline (MC) Trimethoprim/sulfamethoxazole (TS) 0.5 Ceftazidime (TZ) 20-24h. Stenotrophomonas 35 ± 2°C E. coli 25922TM MHA (1 for mucoid Saline Levofloxacin (LE) 48h for slow maltophilia Ambient air E. coli 35218TM (TLc) organisms) Minocycline (MC) growers Ticarcillin/clavulanic acid (TLc) bioMérieux SA English - 3 Etest® Application Guide 16273B - en - 2012/07 FASTIDIOUS ORGANISMS RECOMMENDED INOCULUM INCUBATION SPECIFIC QUALITY CONTROL ORGANISM MEDIA 6) SUGGESTED MIC PANEL 3) COMMENTS 4) PHENOTYPE Suspension Temperature/ McF equivalent Time (h) Strain ATCC® medium Atmosphere Meropenem (MP) Cefotaxime (CT) MHA + 5% blood 0.5 MH broth or Benzylpenicillin (PG) 35 ± 2°C Streptococcus Pneumococci (CLSI) (1 for mucoid 20-24h 49619TM BHI broth Clindamycin (CM) 1) 5% CO pneumoniae MHF (EUCAST) organisms) 2 Vancomycin (VA) Trimethoprim/sulfamethoxazole (TS) Benzylpenicillin (PG) Cefotaxime (CT) MHA + 5% blood 0.5 Chloramphenicol (CL) MH broth or 35 ± 2°C Streptococci (CLSI) (1 for mucoid Ofloxacin (OF) 20-24h S. pneumoniae 49619TM BHI broth 5% CO MHF (EUCAST) organisms) Linezolid (LZ) 1) 2 Vancomycin (VA) Daptomycin (DPC) MH chocolate agar + Broth Abiotrophia & 35 ± 2°C 0.001% pyridoxal HCl + 1 (MH broth or 20-24h 5) 5) Granulicatella spp. 1) 5% CO 0.01% cysteine BHI broth) 2 Amoxicillin/ clavulanic acid (XL) Haemophilus Test 0.5 MH broth or Cefotaxime (CT) Haemophilus 49247TM Haemophilus 35 ± 2°C Media (HTM) (CLSI) (1 for mucoid HTM broth Meropenem (MP) 20-24h influenzae influenzae 5% CO MHF (EUCAST) organisms) (or BHI broth) Trimethoprim/sulfamethoxazole (TS) 2 H. influenzae 49766TM Chloramphenicol (CL) (MP, XM) MHA + 5% blood MH broth or 35 ± 2°C Moraxella catarrhalis 1) (CLSI) 0.5 20-24h 5) 5) BHI broth 5% CO MHF (EUCAST) 2 - For obligate anaerobes, ensure anaerobic Metronidazole (MZ) Brucella agar + 24-72h conditions are Brucella broth Clindamycin (CM) 5% blood + (48h for CM). 35 ± 2°C Bacteroides fragilis 25285TM maintained throughout or MH broth Cefoxitin (FX) Anaerobes vitamin K (1 µg/mL) + 1 Confirm all Anaerobic B. thetaiotaomicron 29741TM processing (or Schaedler Imipenem (IP) hemin (5 µg/mL) (BBA) S results at system Eubacterium lentum 43055TM - DO NOT VORTEX Broth + vit K3) Piperacillin/tazobactam (PTc) (CLSI) 48h. - Anaerobiosis must be Benzylpenicillin (PG) achieved within 1-2 hours for MZ bioMérieux SA English - 4 Etest® Application Guide 16273B - en - 2012/07 RECOMMENDED INOCULUM INCUBATION SPECIFIC QUALITY CONTROL ORGANISM MEDIA 6) SUGGESTED MIC PANEL 3) COMMENTS 4) PHENOTYPE Suspension Temperature/ McF equivalent Time (h) Strain ATCC® medium Atmosphere - 1 strip/90mm plate - Strip handle to be 35 ± 2°C placed at edge of plate. MH broth + Amoxicillin (AC) Micro- - H. pylori colonies are MHA + 5% blood 5% serum Clarithromycin (CH) aerophilic, Helicobacter pylori 1) 3 72h or longer Helicobacter pylori 43504TM pin-point, translucent (≥ 2 weeks old) (CLSI) or BHI broth + Metronidazole (MZ) except MZ - and difficult to see. 5% serum Tetracycline (TC) first 24h Tilt plate and use anaerobic oblique light to read endpoint. Ciprofloxacin (CI) Supplemented GC agar Benzylpenicillin (PG) MH broth 35 ± 2°C Neisseria - 3-4 strips max./150mm Gonococci (CLSI) 0.5 Tetracycline (TC) 20-24h 49226TM (or BHI broth) 5% CO gonorrhoeae plate to facilitate reading MH chocolate agar Ceftriaxone (TX) 2 Spectinomycin (SC) 1) Ciprofloxacin (CI) MHA + 5% blood Benzylpenicillin (PG) Broth 35 ± 2°C S. pneumoniae 49619TM Meningococci 1) (CLSI) 0.5 Trimethoprim/sulfamethoxazole (TS) 24h - Work in BSC (BHI broth) 5% CO E. coli 25922TM MH chocolate agar Meropenem (MP) 2 Ceftriaxone (TX) - 3-4 strips max./150mm plate to facilitate reading - Do not invert plate Ciprofloxacin (CI) MHA + 5% blood 35 ± 2°C - Campylobacter colonies Broth Gentamicin (GM) Campylobacter Campylobacter spp. 1) (CLSI) 1 48-72h
Load more

Recommended publications
  • Ceftazidime for Injection) PHARMACY BULK PACKAGE – NOT for DIRECT INFUSION
    PRESCRIBING INFORMATION FORTAZ® (ceftazidime for injection) PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4­ thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1­ azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]. It has the following structure: The molecular formula is C22H32N6O12S2, representing a molecular weight of 636.6. FORTAZ is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. The Pharmacy Bulk Package vial contains 709 mg of sodium carbonate. The sodium content is approximately 54 mg (2.3mEq) per gram of ceftazidime. FORTAZ in sterile crystalline form is supplied in Pharmacy Bulk Packages equivalent to 6g of anhydrous ceftazidime. The Pharmacy Bulk Package bottle is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous use. THE PHARMACY BULK PACKAGE IS NOT FOR DIRECT INFUSION, FURTHER DILUTION IS REQUIRED BEFORE USE.
    [Show full text]
  • Figure 1: Etest Gradient Configuration When an Etest Gradient Strip Is
    Inoculum preparation Table 1. Recommended media, inoculum and To obtain reproducible MICs from a gradient based Use the inoculum guide in TABLE 1. Emulsify several incubation1). system, the stability of the gradient must be maintai- well-isolated colonies from an overnight agar plate in lêÖ~åáëã= ^Ö~ê= fåçÅìäìã fåÅìÄ~íáçå ned throughout the critical period when the position a suitable suspension medium to achieve the specifi ed Öêçìé ãÉÇá~ of the growth/inhibition edge for a particular bac- inoculum turbidity by comparing to a McFarland pìëéÉåëáçå qìêÄáÇáíó= qÉãéÉê~íìêÉ= ^íãçëéÜÉêÉ qáãÉ= Antimicrobial Susceptibility Testing terium/antibiotic combination is determined. Due turbidity standard. For fastidious organisms such as EjÅc~êä~åÇF Eœ=O=ø`F EÜçìêëF For In Vitro Diagnostic Use to the stability and precision of the Etest predefi ned pneumococci, streptococci, gonococci, anaerobes and gradient, MIC values have been shown to be repro- Haemophilus spp., use the suspension prepared in INTENDED USE ducible and equivalent to those of the CLSI reference broth within 15 minutes. ^ÉêçÄÉë jìÉääÉê= MKURB=k~`ä MKR================== PR=ø` ~ãÄáÉåí NSJOM Etest is a quantitative technique for determining dilution procedures. eáåíçå EN=áÑ=ãìÅçáÇF the antimicrobial susceptibility of Gram negative Inoculation and Gram positive aerobic bacteria such as En- REAGENTS Soak a sterile, non-toxic swab in the inoculum terobacteriaceae, Pseudomonas, Staphylococcus and Etest is supplied in a package of 100 or 30 (some suspension and remove excess fl uid by pressing it lop^L=lopb jìÉääÉê= MKURB=k~`ä MKR PR=ø` ~ãÄáÉåí OQ=lop^==== Enterococcus species and fastidious bacteria, such as reagents) test strips of one antimicrobial agent.
    [Show full text]
  • Clinical Review (Cubicin)
    Clinical Review Amol Purandare, MD NDA 021572 Cubicin (Daptomycin for injection) CLINICAL REVIEW Application Type NDA supplement Application Number(s) 21572 Priority or Standard Priority Submit Date(s) June 30, 2016 Received Date(s) June 30, 2016 PDUFA Goal Date March 30, 2017 (Major amendment) Division / Office DAIP/OAP Reviewer Name(s) Amol Purandare, MD Review Completion Date March 23, 2017 Established Name Daptomycin (Proposed) Trade Name Cubicin Therapeutic Class Cyclic Lipopeptide Applicant Cubist Pharmaceuticals Formulation(s) Injection Dosing Regimen 5 mg/kg (12-<18 years), 7 mg/kg (7-11 years), 9 mg/kg (2-6 years), and 10 mg/kg (1-< 2 years) Indication(s) Complicated Skin and Skin Structure Infections 1 Reference ID: 4075320 Clinical Review Amol Purandare, MD NDA 021572 Cubicin (Daptomycin for injection) Intended Population(s) Ages 1 year to <18 years Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT..........................................6 1.1 Recommendation on Regulatory Action ..............................................................6 1.2 Risk Benefit Assessment .....................................................................................6 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ....6 1.4 Recommendations for Postmarket Requirements and Commitments.................7 2 INTRODUCTION AND REGULATORY BACKGROUND .........................................7 2.1 Product Information .............................................................................................7
    [Show full text]
  • UNASYN® (Ampicillin Sodium/Sulbactam Sodium)
    ® UNASYN (ampicillin sodium/sulbactam sodium) To reduce the development of drug-resistant bacteria and maintain the effectiveness of UNASYN® and other antibacterial drugs, UNASYN should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION UNASYN is an injectable antibacterial combination consisting of the semisynthetic antibacterial ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration. Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid. Chemically, it is monosodium (2S, 5R, 6R)-6-[(R)-2-amino-2-phenylacetamido]-3, 3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate and has a molecular weight of 371.39. Its chemical formula is C16H18N3NaO4S. The structural formula is: COONa O CH 3 N CH O 3 NH S NH 2 1 Reference ID: 4053909 Sulbactam sodium is a derivative of the basic penicillin nucleus. Chemically, sulbactam sodium is sodium penicillinate sulfone; sodium (2S, 5R)-3,3-dimethyl-7-oxo-4-thia- 1-azabicyclo [3.2.0] heptane-2-carboxylate 4,4-dioxide. Its chemical formula is C8H10NNaO5S with a molecular weight of 255.22. The structural formula is: COONa CH 3 O N CH 3 S O O UNASYN, ampicillin sodium/sulbactam sodium parenteral combination, is available as a white to off-white dry powder for reconstitution. UNASYN dry powder is freely soluble in aqueous diluents to yield pale yellow to yellow solutions containing ampicillin sodium and sulbactam sodium equivalent to 250 mg ampicillin per mL and 125 mg sulbactam per mL. The pH of the solutions is between 8.0 and 10.0.
    [Show full text]
  • Severe Sepsis and Septic Shock Antibiotic Guide
    Stanford Health Issue Date: 05/2017 Stanford Antimicrobial Safety and Sustainability Program Severe Sepsis and Septic Shock Antibiotic Guide Table 1: Antibiotic selection options for healthcare associated and/or immunocompromised patients • Healthcare associated: intravenous therapy, wound care, or intravenous chemotherapy within the prior 30 days, residence in a nursing home or other long-term care facility, hospitalization in an acute care hospital for two or more days within the prior 90 days, attendance at a hospital or hemodialysis clinic within the prior 30 days • Immunocompromised: Receiving chemotherapy, known systemic cancer not in remission, ANC <500, severe cell-mediated immune deficiency Table 2: Antibiotic selection options for community acquired, immunocompetent patients Table 3: Antibiotic selection options for patients with simple sepsis, community acquired, immunocompetent patients requiring hospitalization. Risk Factors for Select Organisms P. aeruginosa MRSA Invasive Candidiasis VRE (and other resistant GNR) Community acquired: • Known colonization with MDROs • Central venous catheter • Liver transplant • Prior IV antibiotics within 90 day • Recent MRSA infection • Broad-spectrum antibiotics • Known colonization • Known colonization with MDROs • Known MRSA colonization • + 1 of the following risk factors: • Prolonged broad antibacterial • Skin & Skin Structure and/or IV access site: ♦ Parenteral nutrition therapy Hospital acquired: ♦ Purulence ♦ Dialysis • Prolonged profound • Prior IV antibiotics within 90 days ♦ Abscess
    [Show full text]
  • Antimicrobial Stewardship Guidance
    Antimicrobial Stewardship Guidance Federal Bureau of Prisons Clinical Practice Guidelines March 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Clinical Practice Guidelines Web page to determine the date of the most recent update to this document: http://www.bop.gov/news/medresources.jsp Federal Bureau of Prisons Antimicrobial Stewardship Guidance Clinical Practice Guidelines March 2013 Table of Contents 1. Purpose ............................................................................................................................................. 3 2. Introduction ...................................................................................................................................... 3 3. Antimicrobial Stewardship in the BOP............................................................................................ 4 4. General Guidance for Diagnosis and Identifying Infection ............................................................. 5 Diagnosis of Specific Infections ........................................................................................................ 6 Upper Respiratory Infections (not otherwise specified) ..............................................................................
    [Show full text]
  • Laboratory Manual for Diagnosis of Sexually Transmitted And
    Department of AIDS Control LaborLaboraattororyy ManualManual fforor DiagnosisDiagnosis ofof SeSexxuallyually TTrransmitansmittteded andand RRepreproductivoductivee TTrractact InInffectionsections FOREWORD Sexually Transmitted Infections (STIs) and Reproductive Tract Infections (RTIs) are diseases of major global concern. About 6% of Indian population is reported to be having STIs. In addition to having high levels of morbidity, they also facilitate transmission of HIV infection. Thus control of STIs goes hand in hand with control of HIV/AIDS. Countrywide strengthening of laboratories by helping them to adopt uniform standardized protocols is very important not only for case detection and treatment, but also to have reliable epidemiological information which will help in evaluation and monitoring of control efforts. It is also essential to have good referral services between primary level of health facilities and higher levels. This manual aims to bring in standard testing practices among laboratories that serve health facilities involved in managing STIs and RTIs. While generic procedures such as staining, microscopy and culture have been dealt with in detail, procedures that employ specific manufacturer defined kits have been left to the laboratories to follow the respective protocols. An introduction to quality system essentials and quality control principles has also been included in the manual to sensitize the readers on the importance of quality assurance and quality management system, which is very much the need of the hour. Manual of Operating Procedures for Diagnosis of STIs/RTIs i PREFACE Sexually Transmitted Infections (STIs) are the most common infectious diseases worldwide, with over 350 million new cases occurring each year, and have far-reaching health, social, and economic consequences.
    [Show full text]
  • Synermox 500 Mg/125 Mg Tablets
    New Zealand Data Sheet 1. PRODUCT NAME Synermox 500 mg/125 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Synermox 500 mg/125 mg Tablets: Each film‐coated tablet contains amoxicillin trihydrate equivalent to 500 mg amoxicillin, with potassium clavulanate equivalent to 125 mg clavulanic acid. Excipient(s) with known effect For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Synermox 500 mg/125 mg Tablets: White to off‐white, oval shaped film‐coated tablets, debossed with “RX713” on one side and plain on the other. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications Synermox is indicated in adults and children (see sections 4.2, 4.4 and 5.1) for short term treatment of common bacterial infections such as: Upper Respiratory Tract Infections (including ENT) e.g. Tonsillitis, sinusitis, otitis media. Lower Respiratory Tract Infection e.g. acute exacerbations of chronic bronchitis, lobar and broncho‐pneumonia. Genito‐urinary Tract Infections e.g. Cystitis, urethritis, pyelonephritis, female genital infections. Skin and Soft Tissue Infections. Bone and Joint Infections e.g. Osteomyelitis. Other Infections e.g. septic abortion, puerperal sepsis, intra‐abdominal sepsis, septicaemia, peritonitis, post‐surgical infections. Synermox is indicated for prophylaxis against infection which may be associated with major surgical procedures such as those involving: Gastro‐intestinal tract Pelvic cavity 1 | Page Head and neck Cardiac Renal Joint replacement Biliary tract surgery Infections caused by amoxicillin susceptible organisms are amenable to Synermox treatment due to its amoxicillin content. Mixed infections caused by amoxicillin susceptible organisms in conjunction with Synermox‐susceptible beta‐lactamase‐producing organisms may therefore be treated by Synermox.
    [Show full text]
  • Antibiotic Review
    8/28/19 Disclosure 2 E. Monee’ Carter-Griffin DNP, MA, RN, ACNP-BC Antibiotic has no financial relationships with commercial Review interests to disclose. Any unlaBeled and/or E. Monee’ Carter-Griffin, DNP, MA, RN, ACNP-BC unapproved uses of drugs or products will Be Associate Chair for Advanced Practice Nursing disclosed. University of Texas at Arlington, College of Nursing & Health Innovation Dallas Pulmonary & Critical Care, PA • Identify the general characteristics of • SusceptiBility à determine which antibiotics. antibiotics a bacteria is sensitive to • Discuss the mechanism of action, • à pharmacokinetics, and spectrum of activity MIC lowest concentration of drug that inhiBits growth of the Bacteria for the most common antiBiotic drug classes. Antibiotic Objectives • Identify commonly prescriBed antiBiotics • Trough à lowest concentration of within the drug classes including dosage Lingo drug in bloodstream range and indication for prescribing. – Collect prior to administration of • Identify special considerations for specific drug antibiotics and/or drug classes. • Peak à highest concentration of • Practice appropriate prescriBing for common drug in bloodstream bacterial infections. • Review Basic antiBiotic stewardship 3 4 principles. • Penicillins • Bactericidal or bacteriostatic • Cephalosporins • Narrow or Broad spectrum • Carbapenems General • Can elicit allergic responses Antibiotic • MonoBactam Characteristics • Affect normal Body flora Drug Classes • Macrolides • Fluoroquinolones • Sulfonamides • Tetracyclines 5 6 1 8/28/19 • Penicillins – Natural penicillins 8 – Aminopenicillins Penicillins Penicillins – Anti-staphylococcal penicillins • Mechanism of action àbactericidal à – Anti-pseudomonal penicillins interrupts cell wall synthesis 7 • Pharmacokinetics • Spectrum of Activity – Gram positive organisms Natural – Penicillin G à mostly given IM, But Natural • Streptococcus species (e.g. S. Penicillins one variation can Be given IV Penicillins pyogenes) • Poorly aBsorBed via PO • Some enterococcus species (e.g.
    [Show full text]
  • Eml-2017-Antibacterials-Eng.Pdf
    Consideration of antibacterial medicines as part of the revisions to 2017 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2017 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee, 2017 and this summary should be read in conjunction with the full report (WHO Technical Report Series, No. 1006; http://apps.who.int/iris/bitstream/10665/259481/1/9789241210157-eng.pdf?ua=1). The revised lists of essential medicines (in English) are available as follows: 2017 WHO Model List of Essential Medicines for adults (EML) http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017_FINAL_amend edAug2017.pdf?ua=1 2017 Model List of Essential Medicines for children (EMLc) http://www.who.int/medicines/publications/essentialmedicines/6th_EMLc2017_FINAL_amend edAug2017.pdf?ua=1 Summary of changes to Section 6.2 Antibacterials: Section 6 of the EML covers anti-infective medicines. Disease-specific subsections within Section 6, such as those covering medicines for tuberculosis, HIV, hepatitis and malaria, have been regularly reviewed and updated, taking into consideration relevant WHO treatment guidelines.
    [Show full text]
  • Staphylococcus Aureus Bloodstream Infection Treatment Guideline
    Staphylococcus aureus Bloodstream Infection Treatment Guideline Purpose: To provide a framework for the evaluation and management patients with Methicillin- Susceptible (MSSA) and Methicillin-Resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI). The recommendations below are guidelines for care and are not meant to replace clinical judgment. The initial page includes a brief version of the guidance followed by a more detailed discussion of the recommendations with supporting evidence. Also included is an algorithm describing management of patients with blood cultures positive for gram-positive cocci. Brief Key Points: 1. Don’t ignore it – Staphylococcus aureus isolated from a blood culture is never a contaminant. All patients with S. aureus in their blood should be treated with appropriate antibiotics and evaluated for a source of infection. 2. Control the source a. Removing infected catheters and prosthetic devices – Retention of infected central venous catheters and prosthetic devices in the setting of S. aureus bacteremia (SAB) has been associated with prolonged bacteremia, treatment failure and death. These should be removed if medically possible. i. Retention of prosthetic material is associated with an increased likelihood of SAB relapse and removal should be considered even if not clearly infected b. Evaluate for metastatic infections (endocarditis, osteomyelitis, abscesses, etc.) – Metastatic infections and endocarditis are quite common in SAB (11-31% patients with SAB have endocarditis). i. All patients should have a thorough history taken and exam performed with any new complaint evaluated for possible metastatic infection. ii. Echocardiograms should be strongly considered for all patients with SAB iii. All patients with a prosthetic valve, pacemaker/ICD present, or persistent bacteremia (follow up blood cultures positive) should undergo a transesophageal echocardiogram 3.
    [Show full text]
  • Ceftaroline Fosamil (CPT) Versus DAP Plus Sulfamethoxazole/ Trimethoprim (SMX/TMP) for Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections (BSI) Evan J
    Retrospective Evaluation of Daptomycin (DAP) plus Ceftaroline fosamil (CPT) versus DAP plus Sulfamethoxazole/ Trimethoprim (SMX/TMP) for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections (BSI) Evan J. Zasowski, Pharm.D., BCPS1, Kimberly C. Claeys, Pharm.D.1, Karrine D. Roberts, Pharm.D.2,Donald P. Levine, M.D.3, Susan L. Davis, Pharm.D.1,4, Michael J. Rybak, Pharm.D., M.P.H.1, 3 Address correspondence to: ECCMID 2015 1. Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University, Detroit MI, USA; 2. Department of Pharmacy Services, Detroit Medical Center, Detroit, MI, USA ; P0700 Michael J. Rybak, Pharm.D., M.P.H. 3. Department of Medicine, Division of Infectious Diseases, School of Medicine, Wayne State University, Detroit, MI, USA; 4. Henry Ford Health System, Detroit, MI, USA [email protected] Introduction and Purpose Results • Clinical failure rates and emergence of resistance to first and second- Table 1. Baseline and clinical characteristics Figure 2. Line of therapy* of combination regimen Table 2. Clinical outcomes line treatments for methicillin-resistant Staphylococcus aureus DAP + CPT DAP + SMX/TMP Characteristic p-value 100 DAP + CPT DAP + SMX/TMP N = 23 N = 16 Outcome p-value (MRSA) bloodstream infections (BSI) has led to the exploration of 90 N = 23 N = 16 novel alternative antibiotic treatment strategies Demographics and Comorbid Conditions! 80 Composite failure, n (%)! 7 (30.4)! 7 (43.8)! 0.39! Age, mean (SD)! 57.9
    [Show full text]